Table 3.
Cumulative rates of any opioid use at 5 weeks after randomization (upper panel) and at 26 weeks/end of study (lower panel), by treatment condition (TAU vs XR-NTX + TAU) and by setting in which the patient initiated the study–short-term inpatient (n = 59), versus long-term inpatient (n = 48), versus outpatient (n = 201). Values in the Table are percent using any opioids (N used/N total).
| TAU | XR-NTX + TAU | |
|---|---|---|
| Cumulative Any Opioid Use at 5 Weeks* | ||
| Short-term inpatient (n = 59) |
70 (21/30) | 31 (9/29) |
| Long-term inpatient (n = 48) |
18 (4/22) | 19 (5/26) |
| Outpatient (n = 201) |
42 (43/103) | 16 (16/98) |
| Cumulative Any Opioid Use at End of Study/26 weeks** | ||
| Short-term inpatient (n = 59) |
93 (28/30) | 93 (27/29) |
| Long-term inpatient (n = 48) |
86 (19/22) | 69 (18/26) |
| Outpatient (n = 201) |
74 (76/103) | 59 (58/98) |
For any use by 5 weeks, main effect of treatment (X2(1) = 20.27, p = .0001) and setting are significant X2(2) = 13.83 (p = .001), with any use in the short term inpatient group significantly higher than the long term inpatient (OR = 10.50; 95% CI: 2.76 – 39.92) and outpatient settings (OR = 3.26; 95% CI: 1.36 – 7.80). The treatment by setting interaction was not significant.
For any use by End of Study/26 weeks, main effects of treatment (X2(1) = 6.15, p = .013) and setting (X2(2) = 14.28 (p = .0008) are significant, with any use in the short term inpatient group significantly higher than the long term inpatient (OR = 4.024, 95% CI: 1.183 to 13.687) and outpatient settings (OR = 7.100, 95% CI: 2.455 to 20.532). The treatment by setting interaction was not significant.